Secretagogin is a recently cloned human beta cell-expressed EF-hand calciumbinding protein. Converging evidence indicates that it exerts calcium sensor activity and that it is involved in the regulation of insulin synthesis and secretion. To obtain a potent tool for the extension of its functional analysis in rat in vitro systems, we cloned the rat homologue of human secretagogin. Using comparative sequence analysis, immunostaining, and immunoblotting, we demonstrated a high degree of sequence homology and similar tissue expression patterns of human and rat secretagogin. Highest rat secretagogin expression levels were found in pancreatic beta cells. Basing on newly generated anti-rat secretagogin antibodies, we established a rat secretagogin-specific sandwich capture ELISA and demonstrated release of secretagogin from viable Rin-5F cells. Interestingly, dexamethasone treatment of Rin-5F cells resulted in an increased secretagogin release rate, which was inversely correlated with the secretion of insulin. In contrast, the secretagogin transcription rate was markedly reduced. This resulted in a decreased intracellular secretagogin content under the influence of dexamethasone. Sucrose gradient cell fractionation analysis of Rin-5F cells confirmed the predominant cytosolic localization of secretagogin, with only limited association of secretagogin with insulin granules. Notably, the loss of intracellular secretagogin following dexamethasone treatment affected predominantly the insulin-granule associated secretagogin fractions.
Introduction
In pancreatic beta cells, intracellular calcium is the main down-stream second messenger (3, 20) . Most prominently, oscillations of the intracellular calcium concentration are critically involved in nutrient regulated insulin secretion (7) . Upon glucose metabolism, the ATP/ADP ratio increases with subsequent closure of ATP-dependent potassium-channels, resulting in an increase of the membrane potential (11) . This induces the opening of L-type calcium channels and leads to an increase in the intracellular calcium concentration, which triggers the assembly of the exocytotic machinery with subsequent insulin secretion (5, 32) . In this respect, the additional importance of calcium in vesicle transport to the docking sites, which provides the substrate for the delayed phase of the biphasic insulin secretion, has to be mentioned (5) . In the field of calcium-mediated insulin secretion, the importance of spatial regulation of the calcium concentration, with specific impact of accumulation of voltage gated L-type calcium channels at the site of vesicle docking, seems of further interest (32) .
Additionally, intracellular calcium is involved in the regulation of insulin gene transcription and it has been demonstrated to mediate the activity of various beta-cell expressed kinases (22, 25) .
Interestingly, steroid hormones have been demonstrated to exert profound effects on insulin-transcription and secretion, which are at least partly attributable to altered calcium signalling. For example, dehydroepiandrosterone decreased induced intracellular calcium release with subsequent impairment of insulin secretion (27) . Glucocorticoids influence the expression of the insulin-gene transcription factors HES-1, BETA2/NeuroD and PDX-1, which resulted in impaired insulin synthesis and suppression of beta cell development (17, 41, 42) . Most importantly, dexamethasone exerted direct inhibitory effects on the insulin secreting capacity of mouse pancreatic islets (24) . In light of adequate intracellular calcium signalling, a genomic action of dexamethasone in beta cells, leading to a decrease in the efficacy of cytoplasmic calcium signalling, has been hypothesized as underlying mechanism (24) .
The transduction and efficacy of intracellular calcium signals mainly depends on calcium binding proteins (33) . In the pancreatic beta cell, expression of multiple calcium binding proteins has been described. We recently cloned the calcium binding protein secretagogin from a human beta cell library (46, 47) . Secretagogin belongs to the EF-hand family calcium binding proteins, which exert their calcium binding capacity via the evolutionary highly conserved helix-loop-helix EF-hand motifs (9, 18, 23, 31) . In addition to its strong expression in beta cells, secretagogin is also found in other endocrine tissues and in Page 3 of 29 distinct neurons of the central nervous system (4, 8, 16, 37) . Although the exact function of secretagogin is still a matter of research, its strong expression in insulin-secreting cells (10, 48) , its influence on insulin expression (46) , and recent data indicating glucose-induced upregulation of secretagogin expression in beta cells (1, 43) highlight the functional importance of this calcium binding protein in pancreatic beta-cells.
Due to the lack of human in vitro beta-cell systems, studies on beta-cell function mostly rely on rodent systems (21). In this light, the focus of this study was the characterization of the rat homologue of human secretagogin. Using the rat secretagogin expressing insulinoma cell line Rin-5F, we demonstrated dexamethasone-inducible reduction of intracellular secretagogin. This might contribute to the effects of dexamethasone on insulin homeostasis.
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Methods
Cell culture
Rin-5F cells were cultured in RPMI 1640 supplemented with 10% (v/v) fetal calf serum, 2mM l-glutamin, 100 IU/ml penicillin, and 100µg/ml streptomycin at 37°C and 5% C0 2 . After 5-6 days, cell passage was performed using trypsin (0.25%) and EDTA (0.03%) in Hanks' buffered saline solution.
Cloning of rat secretagogin
RNA was isolated from Rin-5F cells using Trizol (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. First strand cDNA was synthesized using Advantage RT-for PCR Kit (Clontech, Palo Alto, CA, USA). PCR thermal cycling parameters (30 cycles) were set to 94°C (30 sec) for denaturation, 57°C (30 sec) for annealing and 68°C (60 sec) for synthesis. For generation of the full-length coding sequence, PfuUltra™High-Fidelity DNA polymerase (Stratagene, La Jolla, CA) and the following PCR primers were used: forward 5' caccatggacaacgcacacag 3'; reverse 5' tcaggggtttatttttagccc 3'.
The initial denaturation step was performed at 94°C for 4 min. An A-overhang was attached to the PCR products using Taq DNA polymerase (GenScript Corporation, Piscataway, NJ) and the PCR products were cloned into the pCR 2.1 vector (Invitrogen, Carlsbad, CA). The ligated vector was amplified in DH5 E. coli. The insert was cut out using EcoR1 (Roche Diagnostics, Mannheim, Germany) and analyzed by electrophoretic separation. Plasmids containing the right-sized insert were subjected to sequence analysis.
Stimulation assays
For stimulation assays, Rin-5F cells were seeded into 12-well tissue culture plates.
At a confluence of about 75% (~72 hrs of culture), the tissue culture medium was removed and cells were subsequently incubated in native tissue culture medium as described above supplemented with one of the following substrates: 100nM dexamethasone, 10 -5 M LY-294002, 10 -5 M PD-098059, and 500µM cAMP (all from Sigma-Aldrich, Vienna, Austria).
Following an incubation period of 1-24 hrs, tissue culture medium was harvested and frozen at -30°C until further analysis using the newly established rat secretagogin-specific sandwich capture ELISA (see below) and a rat insulin-specific RIA (Linco Research Inc., St. Louis, MO), respectively. Adherent cells were washed 3-times with phosphate buffered saline (PBS) and subjected to cell lysis using Trizol reagent (Roche Diagnostics, Mannheim, Germany).
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Generation of recombinant rat secretagogin variants
To obtain a C-terminally truncated rat secretagogin exopeptide, a plasmid containing a stop codon following amino acid 113 was chosen. It was cloned into the pGEX1 T vector was either frozen at -80°C or lyophilized for further use. Recombinant full-length rat secretagogin was engineered similarly as a GST fusion protein using the pGEX1 T vector and BL21 as the host E.coli strain.
Generation of mouse anti-rat secretagogin monoclonal antibodies
The N-terminal 113aas-exopeptide was emulsified in Freund's adjuvans and used for immunization of 6 weeks old BalbC mice by subcutaneous injection. Additional immunizations were performed on days 14 and 28, using incomplete Freund's adjuvans.
Monoclonal antibody generation was performed as described previously (30) . In brief, the spleens of the immunized mice were removed four days after the last immunization and spleen cell suspensions were fused with the prepared P3 cell line under standard conditions.
Outgrowing clones were screened after a selection period of 14 days by a direct ELISA technique using rat secretagogin-coated plates. Positive clones were further selected by the FACS technique using fixed and permeabilized Rin-5F cells. Clones generating a significant shift in the median fluorescence intensity were subjected to further sub-cloning and expansion.
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Immunostaining
Rin-5F cytoslide preparations or cryosections of rat pancreas were acetone-fixed (3 min). Subsequently, the slides were wetted in PBS. Pancreatic tissue sections and Rin-5F cytoslides were co-incubated (2 hrs) with a rabbit polyclonal anti-secretagogin antibody (16) and with a 1:200 diluted murine monoclonal anti-rat insulin antibody (mAb D3E7, Research
Diagnostics Incorporated, Flanders, NJ). The primary antibodies were followed by a parallel incubation (30 min) with a goat anti-mouse TRITC labeled affinity purified F(ab')2 fragment (for insulin detection) and a goat anti-rabbit Alexa Fluor 488 labeled affinity purified F(ab')2 fragment (for secretagogin detection). The secondary antibodies were obtained from Accurate negative controls with bovine serum albumin-containing PBS omitting the primary antibody were included. All incubation steps were performed in a moist chamber under light protection.
Each incubation step was followed by PBS washes (3x5 min).
Cell fractionation
Rin-5F cells were cultured in 75 cm 2 tissue culture flasks. At 75% confluence, Rin-5F cells were washed twice with ice-cold PBS and subsequently scraped into 2.5ml ice-cold homogenization buffer (250mM sucrose, 3mM imidazol, pH7.4; protease inhibitor supplementation: 10µg/ml aprotinin, 1µg/ml pepstatin, 10µg/ml leupeptin and 0.8mM pefabloc). The cell suspension was then passed 4 times through a 22-G needle. After centrifugation (2500rpm, 10 min, 4°C), the post-nuclear supernatant was overlaid on a discontinuous sucrose gradient (50% and 20%, respectively) in 14x95mm polyallomer centrifuge tubes (Beckman Instruments, Palo Alto, CA) and centrifuged for 1 hr with 40000 rpm at 4°C in the SW40 TI rotor of a L-80 Beckman Ultracentrifuge. The resultant density equilibrium was then fractionated using a peristaltic pump. Starting at the bottom, we collected 21 aliquots. The fractions were subjected to immunoblot analysis for rat secretagogin, SNAP-25, and rat insulin.
Western blot analysis
Protein aliquots were loaded on 12% SDS-PAGE gels, which were run at 200V using Tris-glycine or Tris-tricine (proteins <20kD) running buffer. The protein was electrophoretically transferred onto nitrocellulose using a semidry-blotting device. The blotted membrane was blocked with 10% skim milk for 1 hr. Antigen detection was performed by incubations (2 hrs, constant shaking at room temperature) with the polyclonal rabbit antisecretagogin antibody (16) and quantified by absorbance at 450nm using a Powerwave ELISA reader (Biotek Instruments, Vinooski, VT) including a standard curve with rat recombinant secretagogin. 
Results
Characterization of rat secretagogin
Aiming at the functional analysis of the human beta cell-expressed calcium binding protein secretagogin using the rat insulinoma cell line Rin-5F, our initial attempts focused on the characterization of its rat homologue. For this purpose, we performed reverse transcription PCR of cell extracts derived from Rin-5F cells. Using 5'-and 3'-terminal exonspecific primers according to the rat secretagogin gene sequence (Scgn; GeneID: 306942, location 17p11), we obtained a ~950 bp cDNA PCR product, which was cloned and subjected to sequencing. The predicted amino acid sequence of rat secretagogin and of its human and mouse homologues exhibit a high degree of sequence homology (Fig. 1) . The highest extent of sequence variation is found at the N-terminal protein part of rat secretagogin, which results in loss of 2 EF-hand motifs. The predicted molecular weight of the rat secretagogin full-length protein was 30kDa. The full-length cDNA sequence of rat secretagogin is available under the NCBI accession number NM_201561.
To test if the high extent of sequence homology between human and rat secretagogin is reflected by comparable tissue expression patterns, we performed rat secretagogin expression analysis. Immunoblotting using a rabbit polyclonal anti-secretagogin antibody revealed highest secretagogin expression levels in rat pancreas. Additionally, considerable rat secretagogin expression was found in the prostate and the adrenal glands, with lower rat secretagogin expression levels in other tissues known to contain neuroendocrine cells (Fig. 2) . The immunoblot analysis confirmed the predicted molecular weight of rat secretagogin of ~30kDa, without detection of any protein variants. Confocal immunofluorescence analysis using the rabbit anti-secretagogin antibody revealed strong expression of secretagogin in Rin-5F cells (Fig. 3A, green) . Secretagogin was mainly found at cytoplasmic sites, but was also detectable within the nuclei (Fig. 3, blue) . Rat insulin-specific co-immunostaining (Fig. 3B, red) revealed only a limited extent of intracellular secretagogin/insulin co-localization (Fig. 3C, yellow) . In analogy to its human homologue, confocal immunofluorescence analysis of secretagogin/insulin double-stained rat pancreatic tissue sections showed a nearly exclusive localization of rat secretagogin within the pancreatic islets (Fig. 3D, green) . Additionally, singular cells located within the ductal epithelium were characterized by secretagogin immunostaining (data not shown). Within the islets, rat secretagogin was expressed by beta cells (Fig. 3E, red) , but was also present in insulinnegative cells at the periphery, most probably representing A-, and D-cells. Confirming our findings in Rin-5F cells, rat secretagogin and insulin exhibited only a limited co-localization (Fig. 3F, yellow) .
Rat secretagogin is released from Rin-5F cells
To test if rat secretagogin is released from Rin-5F cells, we measured the rat secretagogin content in Rin-5F tissue culture supernatant using a newly established, rat secretagogin specific sandwich capture ELISA. The species specificity of this ELISA based on a newly generated mouse anti-rat secretagogin antibody, directed against the N-terminus of rat secretagogin. Using this antibody for antigen detection and a rabbit anti-secretagogin antibody as capture antibody, we obtained reproducible linear standard curves within a range from 0.15ng/ml to 16ng/ml. The coefficients of variation for inter-assay variability and intraassay variability were 5% and 7%, respectively. Analysis of Rin-5F supernatant after a culture period of 24 hrs revealed considerable detectability of rat secretagogin, with a release rate of 349±58pg/ml/24hrs.
Consecutively, we screened various agents (100nM dexamethasone, 10
M LY-294002, 10 -5 M PD-098059, and 500µM cAMP) known to potentially affect beta cell physiology for their influence on the secretagogin release rates (Fig. 4) . After an incubation period of 24hrs, Rin-5F cell culture supernatants were harvested and subjected to ELISA analysis. Presented are the mean values ± SD of 4 experiments. Interestingly, dexamethasone exhibited the strongest stimulatory effect on rat secretagogin release, which increased to 717±136pg/ml/24hrs (205±39% of control; p<0.005; paired t-test). Whereas addition of the PI3-kinase inhibitor LY-294002 also exerted stimulatory effects on rat secretagogin release (541±45pg/ml/24hrs; 155±10% of control; p<0.05; paired t-test), exogenous cAMP (475±43pg/ml/24hrs; 136±21% of control), and the MAP-kinase inhibitor PD-098059 (331±46pg/ml/24hrs; 95±13% of control) did not significantly affect the release of rat secretagogin. In parallel with the determination of rat secretagogin content, we measured the insulin concentration in the supernatant of Rin-5F cells. Interestingly, dexamethasone treatment induced an inverse release pattern of insulin and rat secretagogin, with a marked suppression of the insulin release (646±46µU/ml; 33±2% of control; p<0.0001; paired t-test).
In contrast, LY-294002 and PD-098059 had no significant effects on the secretion of insulin (1809±108µU/ml; 93±6% from control and 2158±140µU/ml; 110±7% from control, respectively). Expectedly, cAMP induced an up-regulation of insulin secretion (3161±173µU/ml; 162±9% of control, p<0.005; paired t-test).
Effect of dexamethasone on rat secretagogin expression
To evaluate if the increased release of rat secretagogin from dexamethasone treated Rin-5F cells relies on induction of rat secretagogin expression, Rin-5F cells were incubated with dexamethasone for 1, 6, 12, and 24 hrs, respectively. Subsequently, secretagogin-specific qRT-PCR of Rin-5F cells was performed. All experiments were measured in duplicates, depicted are the mean values ± SD of 3 experiments. Surprisingly, we observed a profound and significant suppression of secretagogin expression in Rin-5F cells under treatment with dexamethasone when compared with untreated Rin-5F cells (Fig. 5,   upper panel) . The suppressive effect became overt after 6 hrs (relative secretagogin expression: 33±2% of control; p<0.0005), reached a maximum after 12 hrs (relative secretagogin expression: 27±20%; p<0.05), and slightly decreased after 24 hrs (relative secretagogin expression: 30±14%; p<0.05). To confirm the reliability of the chosen in vitro system, Pdx-1, which is known to be down-regulated under dexamethasone treatment, was included as control (Fig. 5, lower panel) . Expectedly, Pdx-1 expression decreased under dexamethasone treatment, with a peak suppressive effect after 12 hrs (relative Pdx-1 expression: 17±6%; p<0.005).
Effect of dexamethasone on intracellular rat secretagogin
To characterize the intracellular distribution pattern of rat secretagogin and to evaluate effects of dexamethasone on the compartmentalisation and overall-content of secretagogin, dexamethasone-treated Rin-5F cells and controls were subjected to sucrose gradient fractionation. The individual cell fractions were analysed by parallel immunoblotting against rat secretagogin and SNAP-25, as well as by immunoblotting against rat insulin (Fig.   6A, upper panel) . The rat secretagogin quantity of the individual fractions was determined by subsequent densitometric immunosignal scanning (Fig. 6A, lower panel) . Depicted is one representative experiment out of 3.
Rat secretagogin was found to a majority in the cytosolic fractions. Only a minor portion of rat secretagogin was associated with the secretory granules and with the membrane fractions, which were specified by insulin-and SNAP-25-immunostaining, respectively.
Interestingly, dexamethasone treatment resulted in a decrease of the total Rin-5F secretagogin content ( Fig. 6B ; relative secretagogin content of dexamethasone-treated cells: 76±6.4% of control; p<0.05; n=3). Notably, the decrease of intracellular secretagogin affected predominantly the granular cell compartments (Fig. 6A) . We want to stress that the cell fractionation analysis is in line with the immunfluorescence data and with earlier findings, indicating that only a subfraction of intracellular secretagogin co-localizes with the insulin containing granules.
Discussion
In this study we characterized the rat homologue of the beta cell expressed calcium binding protein secretagogin and demonstrated its release from Rin-5F, which was dexamethasone-inducible.
Due to the limited number of human in vitro systems to study insulin-secreting cells (6, 15, 28, 29) , much of our knowledge on the intracellular signalling pathways in beta cells relies on rodent cell systems (12, 21) . Therefore, the determination of homologous protein characteristics between humans and rodents is essential. Due to its specific expression pattern, human secretagogin was established as a marker for neuroendocrine differentiation in humans (8). The restriction of rat secretagogin expression to the rat pancreatic islets, its strong expression in endocrine cell-containing tissues, as well as its similar intracellular distribution when compared with human secretagogin underline conserved intracellular functions of the protein in humans and rodents. It is noteworthy that we detected exclusively a full-length variant of rat secretagogin. This contrasts our recent findings in humans, which revealed additional expression of truncated secretagogin variants due to post-transcriptional processing (49) .
In parallel to the comparable tissue expression patterns, our data revealed a high degree of sequence homology between human and rat secretagogin. This is in line with other EF-hand family members, highlighting their importance in calcium mediated intracellular processes (23, 31) . The highest extent of sequence variation between the human and rat homologue was found within the N-terminal part of the protein, which results in loss of two N-terminal EF-hand motifs in rat secretagogin. It was recently demonstrated, that human secretagogin, despite of its hexa-EF hand structure, binds only 4 calcium ions, with absence of a calcium binding capacity of the two N-terminal EF-hand motifs (39) . This underlines the minor functional relevance of the N-terminal sequence variation of rat secretagogin when compared with its human counterpart.
Neither human nor rat secretagogin contain a signal peptide sequence, which is a characteristic of secreted proteins. Thus, the detectability of secretagogin in the cell culture supernatant of viable Rin-5F cells stably expressing human secretagogin was a surprising finding (46) . There are two possible explanations for this phenomenon: (i) a spill over effect due to the overexpression of secretagogin in transfected Rin-5F cells; (ii) a release of human secretagogin from the rat insulinoma cell line due to species incompatibilities. However, in this study we specifically detected considerable amounts of rat secretagogin in the supernatant of wild-type Rin-5F cells, implicating secretagogin secretion via signal sequence-independent pathways. At this point, the recently revealed association of secretagogin to the SNARE complex via binding of secretagogin to SNAP-25 seems of interest (39) . The tight association of secretagogin with the secretory machinery might explain its release in the course of insulin granule fusion and membrane pore formation. However, the anti-parallel regulation of insulin and secretagogin release observed in our studies argues against this hypothesis. Alternatively, recently deduced constitutive secretion processes in beta cells might underlie the detectability of secretagogin in Rin-5F supernatant. These include transfer and secretion of immature granules as well as a trans-golgi network independent pathway involving the endosomelysosome compartments (2, 44) . Dexamethasone induced predominantly a decrease of the secretagogin content of the corpuscular cell compartments. This further supports the latter notion and makes a passive trans-membranous diffusion of cytosolic secretagogin to the extra-cellular space less plausible. It has to be stressed that the extent of constitutive secretion seems to depend on the cellular differentiation state (45) . Moreover, there exist considerable differences between individual rodent cell lines (21). These points have to be considered when interpreting our results in respect to other cell lines or in vivo systems.
The diabetogenic effects of glucocorticoids are well known (26) . The underlying mechanisms involve not only down-regulation of GLUT-2 expression with subsequent induction of insulin resistance, but also include direct effects of glucocorticoids on insulin synthesis and secretion (13, 14, 19, 24, 35, 36, 40, 42) . We observed an inverse effect of dexamethasone on insulin and secretagogin secretion of Rin-5F cells, with suppression of insulin secretion but induction of secretagogin release when compared with untreated cells. At this point, the disproportionate secretion of insulin and islet amyloid polypeptide under the influence of dexamethasone, which was also attributed to constitutive islet amyloid polypeptide secretion, has to be mentioned (34, 38, 45) . In parallel, dexamethasone strongly inhibits secretagogin expression in Rin-5F cells, resulting in a reduction of the intracellular secretagogin content under the treatment of dexamethasone. Basing on its calcium binding capability, secretagogin exerts rather calcium sensor than calcium buffer functions (39) . Thus, especially the loss of the secretagogin fraction associated with the insulin secretion machinery might result in a decreased efficacy of calcium responsiveness under dexamethasone treatment. At this point it seems of specific interest, that attenuation of calcium signalling has been hypothesized to underlie the impaired insulin secretion observed under the influence of dexamethasone (24) .
In conclusion, our data demonstrate a high degree of homology between the sequences and tissue expression patterns of human and rat secretagogin, which implicates comparable functions. Furthermore, we provide evidence for dexamethasone-induced loss of intracellular secretagogin. This might underlie the impaired calcium-sensing efficacy observed under the influence of dexamethasone. cells. Using a newly established, rat secretagogin specific sandwich capture ELISA, we confirmed release of rat secretagogin from viable Rin-5F cells. In parallel, the insulin secretion rates of Rin-5F cells were determined using a rat insulin specific radioimmunoassay.
Legends
Interestingly, this revealed anti-parallel effects of dexamethasone (Dex, 100nM) on the secretagogin and insulin-release rates, with induction of rat secretagogin release from Rin-5F cells. Exogenous cAMP (500µM) exerted minor stimulatory effects on both, insulin and rat secretagogin, whereas the PI-3 kinase inhibitor LY-294002 (LY29, 10 -5 M) stimulated exclusively the release of rat secretagogin, but had no effect on the insulin secretion capacity.
The MAP-kinase inhibitor PD-098059 (PD-09, 10 -5 M) influenced neither the insulin-nor the secretagogin release rates. All experiments were performed in quadruplicates, depicted are the mean values ± SD ( * p<0.05; ** p<0.005; *** p<0.0001; paired t-test). All experiments were performed in triplicates. Depicted are the mean values ± SD ( * p<0.05; ** p<0.005; paired t-test). 
